Protalix BioTherapeutics, Inc. has completed a private stock placement
Protalix BioTherapeutics, Inc. has raised funds to refinance the company for further development.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received the approval of the US Food and Drug Administration, for the treatment of Gaucher disease.
Oaklins’ team in Israel advised Protalix BioTherapeutics, Inc. and acted as a member in the distributors’ consortium.
Talk to the deal team
PrincipalTel Aviv, Israel
PartnerTel Aviv, Israel
SupportTel Aviv, Israel
ALRAG Invest Germany has issued bonds
ALRAG Invest Germany GmbH & Co. KG has completed a fundraising to develop its portfolio.Learn more
Ideagen has completed a US$105 million debt refinancing
Ideagen Plc. has raised funds to support its next phase of growth.Learn more
Palmatum has raised capital to build a major commercial facility in Montreal
The founder of Project Palmatum has raised capital in order to build and operate Montreal’s major and most innovative commercial B2C trade floor – 150,000 sqft dedicated to garden and home interior.Learn more